Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Total Valuation
Beam Therapeutics has a market cap or net worth of $2.83B. The enterprise value is $1.57B.
Market Cap$2.83B
Enterprise Value$1.57B
Share Statistics
Beam Therapeutics has 101,474,945 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding101,474,945
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Beam Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -44.44%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-44.44%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee161.62K
Profits Per Employee-958.63K
Employee Count393
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Beam Therapeutics is ―. Beam Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio32.14
PB Ratio2.78
Price to Fair Value2.78
Price to FCF-5.73
Price to Operating Cash Flow-6.89
PEG Ratio-0.03
Income Statement
In the last 12 months, Beam Therapeutics had revenue of 63.52M and earned -376.74M in profits. Earnings per share was -4.58.
Revenue63.52M
Gross Profit-304.04M
Operating Income-415.57M
Pretax Income-376.70M
Net Income-376.74M
EBITDA-393.64M
Earnings Per Share (EPS)-4.58
Cash Flow
In the last 12 months, operating cash flow was -338.18M and capital expenditures -14.18M, giving a free cash flow of -352.36M billion.
Operating Cash Flow-338.18M
Free Cash Flow-352.36M
Free Cash Flow per Share-3.47
Dividends & Yields
Beam Therapeutics pays an annual dividend of $0.225, resulting in a dividend yield of ―
Dividend Per Share$0.225
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.08
52-Week Price Change-3.24%
50-Day Moving Average25.21
200-Day Moving Average21.00
Relative Strength Index (RSI)59.32
Average Volume (3m)1.91M
Important Dates
Beam Therapeutics upcoming earnings date is Mar 3, 2026, Before Open (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Beam Therapeutics as a current ratio of 4.82, with Debt / Equity ratio of 15.67%
Current Ratio4.82
Quick Ratio4.82
Debt to Market Cap0.00
Net Debt to EBITDA0.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Beam Therapeutics has paid 39.00K in taxes.
Income Tax39.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Beam Therapeutics EV to EBITDA ratio is -5.00, with an EV/FCF ratio of -5.39.
EV to Sales30.24
EV to EBITDA-5.00
EV to Free Cash Flow-5.39
EV to Operating Cash Flow-5.53
Balance Sheet
Beam Therapeutics has $1.07B in cash and marketable securities with $151.42M in debt, giving a net cash position of $923.55M billion.
Cash & Marketable Securities$1.07B
Total Debt$151.42M
Net Cash$923.55M
Net Cash Per Share$9.10
Tangible Book Value Per Share$8.91
Margins
Gross margin is -14.28%, with operating margin of -654.25%, and net profit margin of -593.13%.
Gross Margin-14.28%
Operating Margin-654.25%
Pretax Margin-593.06%
Net Profit Margin-593.13%
EBITDA Margin-604.51%
EBIT Margin-654.25%
Analyst Forecast
The average price target for Beam Therapeutics is $43.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.00
Price Target Upside54.84% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast-84.07%
EPS Growth Forecast-157.71%